Alnylam Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $4,054 Mil.
Alnylam Pharmaceuticals's quarterly Total Liabilities
declined
from Sep. 2025 ($4,617.77 Mil) to Dec. 2025 ($4,177.16 Mil) and
declined
from Dec. 2025 ($4,177.16 Mil) to Mar. 2026 ($4,054.17 Mil).
Alnylam Pharmaceuticals's annual Total Liabilities
increased
from Dec. 2023 ($4,050.52 Mil) to Dec. 2024 ($4,172.90 Mil) and
increased
from Dec. 2024 ($4,172.90 Mil) to Dec. 2025 ($4,177.16 Mil).
Alnylam Pharmaceuticals Total Liabilities Related Terms
Alnylam Pharmaceuticals Total Liabilities Historical Data
* Premium members only.
The historical data trend for Alnylam Pharmaceuticals's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Alnylam Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a Total Liabilities of $4,054 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Total Liabilities too high?
Alnylam Pharmaceuticals' current Total Liabilities is $4,054 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Total Liabilities compare to RVMD and ONC?
Alnylam Pharmaceuticals' Total Liabilities of $4,054 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Total Liabilities is $4,054 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $517.19, compared to a current price of $312.13 — trading 39.6% below its estimated fair value. The current Total Liabilities is $4,054 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Total Liabilities is $4,054 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $312.13 is trading 39.6% below its estimated GF Value™ of $517.19.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Total Liabilities: $4,054 Mil
GF Value™: $517.19 vs. price of $312.13 (39.6% below fair value)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
